These findings raise the possibility that tumours with increased expression of CDK7 may be more sensitive to CDK7 inhibition, particularly in the case of ER+ breast cancer, where the CDK7-activated nuclear receptor, ER⍺, drives tumour progression. Here, CDK7 is linked to breast carcinoma.